[Clinical value of a new method of therapeutic control of heparin].
A modification of thrombosis time (TT) for therapeutic control of heparin (TTDT), is described. A useful dose of heparin increases plasma TT, which on dilution with fresh plasma rich in platelets (250 +/- 50 x 10(9)/1) at a dilution of 1:4 to 1:8 (+/-20%), causes the increased plasma TT to return to normal values. Three coagulation tests used simultaneously were tried: plasma recalcification time, partially activated thromboplastin time, and TT, used simultaneously in 30 samples of platelet rich fresh normal plasma with different concentrations of heparin (0.05 to 1.0 mu/ml). Results show that modified TT is the most sensitive and reproducible test to detect varying heparin dosage. Fifty two patients without coagulation deficiencies and with various clinical thrombi, and 22 with generalized intravascular coagulation (CID) treatment with 100mu of heparin XK of body weight every 4 to 6 hours, were studied. Results are described. Advantages of TRDT for therapeutic control of heparin are discussed.
D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D001780:Blood Coagulation Tests / Q000379:methods*; D005069:Evaluation Studies as Topic; D006493:Heparin / Q000097:blood* / Q000627:therapeutic use; D006801:Humans
D006493:Heparin
Utilidad clínica de un nuevo método para el control terapéutico de la heparina.